TITLE

Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study

AUTHOR(S)
Krasuski, Richard A.; Doeppenschmdt, Dennis; Henry, John S.; Smith, P. Brad; Adinaro, Joseph; Beck, Rachel; Thompson, Christopher M.
PUB. DATE
September 2005
SOURCE
Mayo Clinic Proceedings;Sep2005, Vol. 80 Issue 9, p1163
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To examine the safety and efficacy of switching from simvastatin to atorvastatin In patients who had either an inadequate lipid-lowering response with, or an adverse reaction to, simvastatin. PATIENTS AND METHODS: The Conversion to Atorvastatin in Patients intolerant or Refractory to Simvastatin Therapy (CAPISH) study was designed in 2 parts: a retrospective cohort study of patients (group A), Identified from a large pharmacy database, who converted from simvastatin to atorvastatin at a single academic military medical center (between April 1998 and March 2002) and a prospective cohort study of patients (group B) monitored In a lipid clinic at the same institution (between April 2002 and March 2003). Group A was identified by 2 or more simvastatin prescription fills and at least 1 atorvastatin prescription fill. Group B was Identified by a physician-perceived need to switch from simvastatin to atorvastatin. Clinical, pharmaceutical, and laboratory records of both cohorts were reviewed. RESULTS: Approximately 1 In 4 simvastatin-treated patients discontinued therapy during a 4-year period. The most common reason for switching to atorvastatin was inadequate low-density lipoprotein (LDL) cholesterol control, although asymptomatic creatine kinase (CK) elevation and myalglas were also common. In most cases of myositis and In nearly all cases of rhabdomyolysis, patients were taking 80 mg of simvastatin. Achievement of National Cholesterol Education Program LDL cholesterol goals increased from 25% to 63% in group A and from 13% to 78% in group B, both P<.001. Significant reductions in CK also were seen in both groups. Adherence to atorvastatin was greater than 80% in both groups after 28.1±13.2 months (group A, 841 patients) and 8.1±3.8 months (group B, 104 patients). Among patients not taking atorvastatin at follow-up, 58% were no longer taking statins. CONCLUSION: Atorvastatin was well tolerated in patients who previously were taking simvastatin. Serum lipid panels were improved substantially and CK levels were decreased without compromise to patient safety.
ACCESSION #
18184309

 

Related Articles

  • Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Pisciotta, Livia; Bellocchio, Antonella; Bertolini, Stafano // Lipids in Health & Disease;2012, Vol. 11 Issue 1, p123 

    Background: Although statins (STs) are drugs of first choice in hypercholesterolemic patients, especially in those at high cardiovascular risk, some of them are intolerant to STs or refuse treatment with these drugs. In view of this, we have evaluated the lipid-lowering effect of a nutraceutical...

  • Diltiazem/simvastatin interaction.  // Reactions Weekly;2/19/2011, Issue 1339, p18 

    The article describes the case of a 59-year-old man who developed rhabdomyolysis after receiving concomitant oral simvastatin for hypercolesterolemia and coronary heart disease and oral diltiazem for angina pectoris.

  • Blood Lipids. Tolmach Sugerman, Deborah // JAMA: Journal of the American Medical Association;10/23/2013, Vol. 310 Issue 16, p1751 

    This article provides information on hyperlipidemia and discusses the types of blood lipids. Problems from hyperlipidemia include the risk of developing metabolic syndrome, diabetes and heart diseases. Lifestyle treatments for hyperlipidemia include eating a healthy, low-fat diet and exercise....

  • Rhabdomyolysis in Community Acquired Bacterial Sepsis - A Retrospective Cohort Study. Kumar, Anita A.; Bhaskar, Emmanuel; Shantha, Ghanshyam Palamaner Subash; Swaminathan, Porchelvan; Abraham, Georgi // PLoS ONE;2009, Vol. 4 Issue 9, p1 

    Background and Objectives: Rhabdomyolysis is often associated with sepsis and gram positive bacterial pathogens are reported to be the most frequent cause of sepsis induced rhabdomyolysis. We report the pattern of infecting bacterial pathogens and associated causal factors in a South-Indian...

  • Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin. Catapano, Alberico L. // Current Vascular Pharmacology;Mar2012, Vol. 10 Issue 2, p257 

    3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely prescribed therapeutic class of drugs worldwide, with established clinical benefits both in terms of improving serum lipid profiles and reducing cardiovascular events and mortality. Although statins have a...

  • Atorvastatin.  // Reactions Weekly;8/13/2011, Issue 1364, p9 

    The article describes the case of a man who developed rhabdomyolysis during treatment with atorvastatin for his myocardial infarction.

  • Atorvastatin/fusidic acid interaction.  // Reactions Weekly;3/26/2011, Issue 1344, p8 

    The article describes the case of a 58-year-old man who developed rhabdomyolysis while receiving concomitant treatment with atorvastatin and fusidic acid therapy.

  • Atorvastatin/simvastatin/fusidic acid interaction.  // Reactions Weekly;7/24/2010, Issue 1311, p13 

    The article describes the cases of four patients with type 2 diabetes melliitus who developed rhabdomyolysis due to drug interaction between atorvastatin, simvastatin and fusidic acid.

  • Statins, macrolides and rhabdomyolysis.  // Australian Journal of Pharmacy;Dec2010, Vol. 91 Issue 1087, p39 

    The article focuses on the reports received by the Therapeutic Goods Administration (TGA) as of July 2010, which show that 80% of the patients who received statin and macrolide antibiotic had at least one risk factor for myopathy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics